MannKind Corporation

NasdaqGM:MNKD 株式レポート

時価総額：US$1.9b

MannKind マネジメント

マネジメント 基準チェック /34

MannKindの CEO はMichael Castagnaで、 May2017年に任命され、 の在任期間は 7.5年です。 の年間総報酬は$ 7.07Mで、 9.9%給与と90.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.83%を直接所有しており、その価値は$ 15.60M 。経営陣と取締役会の平均在任期間はそれぞれ7.3年と4.8年です。

主要情報

Michael Castagna

最高経営責任者

US$7.1m

報酬総額

CEO給与比率9.9%
CEO在任期間7.5yrs
CEOの所有権0.8%
経営陣の平均在職期間7.3yrs
取締役会の平均在任期間4.8yrs

経営陣の近況

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

CEO報酬分析

MannKind の収益と比較して、Michael Castagna の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

US$22m

Jun 30 2024n/an/a

US$12m

Mar 31 2024n/an/a

US$8m

Dec 31 2023US$7mUS$702k

-US$12m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$4mUS$623k

-US$87m

Sep 30 2022n/an/a

-US$98m

Jun 30 2022n/an/a

-US$88m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$4mUS$598k

-US$81m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$4mUS$495k

-US$57m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$44m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$2mUS$511k

-US$52m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$61m

Mar 31 2019n/an/a

-US$71m

Dec 31 2018US$2mUS$500k

-US$87m

Sep 30 2018n/an/a

-US$110m

Jun 30 2018n/an/a

-US$119m

Mar 31 2018n/an/a

-US$131m

Dec 31 2017US$1mUS$459k

-US$117m

報酬と市場: Michaelの 総報酬 ($USD 7.07M ) は、 US市場 ($USD 5.34M ) の同規模の企業の平均を上回っています。

報酬と収益: Michaelの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Michael Castagna (47 yo)

7.5yrs

在職期間

US$7,068,114

報酬

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Michael Castagna
CEO & Director7.5yrsUS$7.07m0.83%
$ 15.6m
Lauren Sabella
Chief Operating Officer1.7yrsUS$2.74m0.025%
$ 478.2k
David Thomson
Executive VP22.8yrsUS$2.34m0.17%
$ 3.1m
Stuart Tross
Executive VP and Chief People & Workplace Officer7.9yrsUS$2.22m0.22%
$ 4.1m
Christopher Prentiss
Chief Financial Officerless than a yearデータなしデータなし
Sanjay Singh
Executive Vice President of Technical Operations2.1yrsUS$1.12m0.035%
$ 650.2k
Rosabel Alinaya
VP of Investor Relations & Treasury7.3yrsUS$519.59kデータなし
John Bedard
Senior Vice President of Worldwide Regulatory Affairs19.1yrsデータなしデータなし
James McCauley
Chief Commercial Officer7.3yrsUS$921.51kデータなし
Burkhard Blank
Executive VP of Research & Development and Chief Medical Officer1.5yrsデータなし0.070%
$ 1.3m

7.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: MNKDの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称ポジション在職期間報酬所有権
Michael Castagna
CEO & Director7.5yrsUS$7.07m0.83%
$ 15.6m
Ronald Consiglio
Independent Director21.1yrsUS$241.73k0.043%
$ 805.2k
Kent Kresa
Chairman Emeritusless than a yearUS$240.64k0.096%
$ 1.8m
Christine Ann Mundkur
Independent Director6yrsUS$226.73k0.010%
$ 188.3k
Michael Friedman
Independent Director20.9yrsUS$229.23k0.0054%
$ 101.6k
Anthony Hooper
Independent Director4.8yrsUS$233.14k0.064%
$ 1.2m
James Shannon
Independent Chairman9.5yrsUS$255.64k0.0089%
$ 166.3k
Sabrina Kay
Independent Director3.9yrsUS$221.73k0.039%
$ 727.8k
Thomas Blevins
Member of Scientific Advisory Board3.3yrsデータなしデータなし
Steven Binder
Directorless than a yearUS$2.34m0.20%
$ 3.7m
Jennifer Grancio
Independent Director4.7yrsUS$221.73k0.040%
$ 752.7k
Davida Kruger
Member of Scientific Advisory Board3.3yrsデータなしデータなし

4.8yrs

平均在職期間

64.5yo

平均年齢

経験豊富なボード: MNKDの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。